Evaluation of the effect of SGLT-2 inhibitors on atrial fibrillation recurrence in diabetic patients

Yarar M., ARI H., Ari S., Tütüncü A., Melek M., BOZAT T.

Expert Opinion on Pharmacotherapy, cilt.26, sa.11-12, ss.1343-1349, 2025 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 11-12
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1080/14656566.2025.2527189
  • Dergi Adı: Expert Opinion on Pharmacotherapy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1343-1349
  • Anahtar Kelimeler: Diabetes mellitus, atrial fibrillation, SGLT-2 inhibitor, cardioversion, recurrence
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: The aim of this study was to investigate the effect of SGLT-2 (sodium glucose cotransporter-2) inhibitors on AF (atrial fibrillation) recurrence in patients diagnosed with diabetes mellitus (DM) who underwent Direct Current Cardioversion (DCCV) in our clinic. Research design and methods: Consecutive DCCV was performed to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who didn’t use SGLT-2 inhibitors). The two groups (SGLT-2 inhibitor user group and control group) were monitored for AF recurrence on the first day, then at one, three, and six months after CV. Results: During the six-month follow-up period, AF recurrence developed in 24 (40%) patients in SGLT-2 inhibitor group and in 35 (58.3%) of the control group, p = 0.04. In univariable analysis, AF duration, non-use of SGLT-2 inhibitor, left atrium diameter, TAPSE value and in multivariable analysis, AF duration OR: 4.98; 95%CI (2.39–10.38), p < 0,001 and non-use of SGLT-2 inhibitors OR: 0.35; 95%CI (0.13–0.90), p = 0.03 were found to be independent predictors for AF recurrence. Conclusion: AF recurrence ratio is significantly lower in patients using SGLT-2 inhibitors, in six-month follow-up period. AF duration and SGLT-2 inhibitor non-use were independent predictors, for AF recurrence in DM patients (NCT06951737). Clinical trial registration: www.clinicaltrials.gov identifier is: NCT06951737.